A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

ESMO Open - Tập 2 - Trang e000174 - 2017
Yi-Long Wu1, Chang-Li Wang2, Yan Sun3, Mei-Lin Liao4, Zhong-Zhen Guan5, Zhi-Min Yang6, Qing-Hua Zhou7, Shun Lu4, Ying Cheng8, Xiao-Qing Liu9, Xu-Chao Zhang1, Caicun Zhou10, Jie Wang11, Qing Zhou1, Yong Song12, Bao-Hui Han13, Zhi-Yong Ma14, Fan Yang15, Qun Wang16, Shao-Kun Chuai17
1Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
2Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
3National GCP Center for Anticancer Agents, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China
5Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China
6The Center for Drug Evaluation, China Food and Drug Administration, Beijing, China
7Lung Cancer Center, West China Hospital, Chengdu, China
8Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun, China
9Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Beijing, China
10Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China
11Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
12Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
13Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China
14Department of Medical Oncology, Henan Cancer hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
15Department of Thoracic Surgery, Peking University People Hospital, Beijing, China
16Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
17Burning Rock Biotech, Guangzhou, China

Tài liệu tham khảo

Jameson, 2015, Precision medicine-personalized, problematic, and promising, N Engl J Med, 372, 2229, 10.1056/NEJMsb1503104 Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 Kwak, 2009, Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066, J Clin Oncol, 27, 3509, 10.1200/jco.2009.27.15_suppl.3509 Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, 13, 1011, 10.1016/S1470-2045(12)70344-3 Kim, 2012, Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung Cancer [abstract], J Clin Oncol, 30 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440 Lu, 2016, Phase 3 study of first-line crizotinib vs pemetrexed- Cisplatin/Carboplatin (PCC) in east asian patients (pts) with ALK+ advanced non-squamous nonsmall cell lung Cancer (NSCLC) [abstract], J Clin Oncol, 34 Masuda, 2016, Clinical and biological significance of circulating tumor cells in cancer, Mol Oncol, 10, 408, 10.1016/j.molonc.2016.01.010 Alix-Panabières, 2016, Functional studies on circulating and disseminated tumor cells in carcinoma patients, Mol Oncol, 10, 443, 10.1016/j.molonc.2016.01.004 Heitzer, 2015, Circulating tumor DNA as a liquid biopsy for cancer, Clin Chem, 61, 112, 10.1373/clinchem.2014.222679 Snyder, 2016, Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin, Cell, 164, 57, 10.1016/j.cell.2015.11.050 Taverna, 2016, Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice, Oncotarget, 7, 28748, 10.18632/oncotarget.7638 Ettinger, 2014, Non-small cell lung cancer, version 1.2015, J Natl Compr Canc Netw, 12, 1738, 10.6004/jnccn.2014.0176 Mok, 2015, Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with First-line intercalated erlotinib and chemotherapy, Clin Cancer Res, 21, 3196, 10.1158/1078-0432.CCR-14-2594 Thress, 2015, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med, 21, 560, 10.1038/nm.3854 Oxnard, 2015, Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer [abstract], J Thorac Oncol, 10, S207 Shaw, 2016, Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F, N Engl J Med, 374, 54, 10.1056/NEJMoa1508887 Diaz, 2014, Liquid biopsies: genotyping circulating tumor DNA, J Clin Oncol, 32, 579, 10.1200/JCO.2012.45.2011 Newman, 2016, Integrated digital error suppression for improved detection of circulating tumor DNA, Nat Biotechnol, 34, 547, 10.1038/nbt.3520 Bayarri-Lara, 2016, Circulating tumor cells identify early recurrence in patients with Non-Small cell lung Cancer undergoing radical resection, PLoS One, 11, 10.1371/journal.pone.0148659 Lancet, 2016, Liquid cancer biopsy: the future of cancer detection?, Lancet Oncol, 17, 123, 10.1016/S1470-2045(16)00016-4
Thông tin
Thông tin xuất bản

ESMO Open

Tập 2

e000174

Thông tin tác giả